Vistra Corp. is experiencing a complex phase as its stock remains well below its 52-week high despite a year-to-date gain of over 17%. The company achieved a notable net income of $652 million in Q3 2025 and has been upgraded to investment grade, prompting Morgan Stanley to raise its price target to $228. While Vistra's focus on expanding its nuclear portfolio aligns with growing demand in key markets, reported revenues fell significantly short of expectations, underscoring ongoing market challenges.